Key facts
- This page summarizes Aster Angagaw's Form 4 filing for Lucid Diagnostics Inc. (LUCD).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 23 Feb 2022, 19:24.
Aster Angagaw - 18 Feb 2022 Form 4 Insider Report for Lucid Diagnostics Inc. (LUCD)
- Reporting relationship
- Director
- Issuer ticker
- LUCD
- Reported as of
- 18 Feb 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 23 Feb 2022, 19:24:10 UTC
- Prior SEC filing
- 13 Oct 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Aster Angagaw
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Aster Angagaw filed Form 4 for Lucid Diagnostics Inc. (LUCD) on 23 Feb 2022.
Change
- Previous filing in this sequence was filed on 13 Oct 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
LUCD
transaction
Derivative
Employee stock option (right to buy)
Award
- Transaction value
- $0
- Shares
- +59,000
- Change %
- Price
- $0.000000
- Shares after
- 59,000
- Date
- 18 Feb 2022
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 59,000
- Exercise price
- $3.95
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The option vests in 12 quarterly installments, with first installment vesting March 31, 2022.